ELVN · Enliven Therapeutics Inc
United States · RS rating 60 · As of 2026-11-03
| Price | 44.83 USD |
|---|---|
| 1-day change | +0.5% |
| RS rating (overall / 1M / 3M / 12M) | 60 / 53 / 26 / 93 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 35 / 33 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -50.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +26.7% |
| Market cap (USD) | $2.6B |